Browsing Tag
Johnson & Johnson
102 posts
Janssen Covid‑19 vaccine gets conditional marketing authorization in EU
The European Commission has granted a conditional marketing authorization (CMA) for the single dose Janssen Covid‑19 vaccine developed…
J&J Ad26.COV2.S COVID-19 vaccine gets FDA emergency use authorization
Johnson & Johnson (J&J) said that the US Food and Drug Administration (FDA) has given emergency use authorization…
FDA grants emergency use authorization to Janssen COVID-19 vaccine
The US Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) for the Janssen COVID-19…
Janssen Pharmaceutical’s DARZALEX FASPRO gains FDA approval for AL amyloidosis treatment
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has secured FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj),…
Janssen seeks expanded approval for DARZALEX in treating AL amyloidosis
Janssen Pharmaceutical Companies of Johnson & Johnson has recently submitted a Type II variation application to the European…
Johnson & Johnson strikes key deal with EC for JNJ-78436735 Covid-19 vaccine supply
Johnson & Johnson (J&J) has announced a significant development in its efforts to combat the Covid-19 pandemic, revealing…
J&J begins phase 3 ENSEMBLE Covid-19 vaccine trial for JNJ-78436735
ENSEMBLE Covid-19 vaccine trial : Johnson & Johnson (J&J) has launched a multi-nation phase 3 trial called ENSEMBLE…
Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J
J&J acquisition of Momenta Pharmaceuticals : US healthcare giant Johnson & Johnson (J&J) has signed a $6.5 billion…
From biosimilars to biotech gold: How Momenta scored a $6.5bn exit with J&J
Johnson & Johnson is acquiring Momenta Pharmaceuticals for $6.5 billion to expand its autoimmune pipeline. Find out what makes nipocalimab worth the bet.
Janssen Covid-19 vaccine candidate Ad26.COV2.S bags $1bn deal from US govt
Johnson & Johnson (J&J) said that its subsidiary Janssen Pharmaceutical has agreed to manufacture and supply 100 million…